Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical study of BIO101 (20-hydroxyecdysone) in obesity.
The study will measure muscle strength, mobility and body composition. It is due to start mid-2024 in the United States and could be extended to Europe.
Biophytis expects preliminary results in 2025 and is seeking funding and partnerships to complete the study.
Camurus launches Oczyesa in Germany for patients with acromegaly
Servier's VORANIGO (vorasidenib) receives Prix Galien USA Award
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
GenSight Biologics secures FDA authorisation for expanded access to GS010/LUMEVOQ in the US
Ascletis Pharma Inc selects ASC36 as clinical development candidate
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
Samsung Bioepis to assume European commercialisation of BYOOVIZ (ranibizumab) from January 2026
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities